View : 14 Download: 0

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Title
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Authors
Godman, BrianHill, AndrewSimoens, StevenSelke, GisbertSelke Krulichova, IvaZampirolli Dias, CarolinaMartin, Antony P.Oortwijn, WijaTimoney, AngelaGustafsson, Lars L.Voncina, LukaKwon, Hye-YoungGulbinovic, JolantaGotham, DzintarsWale, JanetDa Silva, Wania CristinaBochenek, TomaszAllocati, EleonoraKurdi, AmanjOgunleye, Olayinka O.Meyer, Johanna C.Hoxha, IrisMalaj, AdmirHierlander, ChristianSauermann, RobertHamelinck, WouterPetrova, GuenkaLaius, OttLangner, IreneYfantopoulos, JohnJoppi, RobertaJakupi, ArianitGreiciute-Kuprijanov, IevaVella Bonanno, PatriciaPiepenbrink, Jf (Hans)de Valk, VincentWladysiuk, MagdaleneMarkovic-Pekovic, VandaMardare, IleanaFurst, JurijTomek, DominikObach Cortadellas, MerceZara, CorinnePontes, CaridadMcTaggart, StuartLaba, Tracey-LeaMelien, OyvindWong-Rieger, DurhaneBae, SeungJinHill, Ruaraidh
Ewha Authors
배승진
SCOPUS Author ID
배승진scopus
Issue Date
2021
Journal Title
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
ISSN
1473-7167JCR Link

1744-8379JCR Link
Citation
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH vol. 21, no. 4, pp. 527 - 540
Keywords
Alternative pricing approachescancer medicineseuropemanaged entry agreementsmulticriteria decision analysesminimum effectiveness criteriapayerstransparent pricing approachestiered pricing approaches
Publisher
TAYLOR &

FRANCIS LTD
Indexed
SCIE; SSCI; SCOPUS WOS scopus
Document Type
Article
Abstract
Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.
DOI
10.1080/14737167.2021.1884546
Appears in Collections:
약학대학 > 약학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE